Epsylon participated in the construction of biologic production facilities to support the long-term development of Canada’s ability to protect its citizens’ health.
The production centre was completed and made operational in record time. This new infrastructure has strengthened Canada’s overall readiness for biofabrication and preparedness in response to a pandemic by allowing vaccines and other biologic drugs to be developed entirely in Canada, from invention through to the final product.